NCT02586129

Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 249 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

Detailed description

This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes. In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755 for 16 weeks. In Metformin treatment group, 88 subjects will be assigned and the subjects administer Metformin for 16 weeks. In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer Rosuvastatin for 16 weeks.

Conditions

• Dyslipidemia
• Type II Diabetes

Interventions

Type	Name	Description
DRUG	YH14755	20/1500mg, QD
DRUG	Metformin	1500mg, QD
DRUG	Rosuvastatin	20mg, QD

Timeline

• Start date: 2015-11-04
• Primary completion: 2017-07-07
• Completion: 2017-07-07
• First posted: 2015-10-26
• Last updated: 2018-10-03

Locations

1 site across 1 country: South Korea